0
Abstract: Poster Presentations |

PRECLINICAL COMPARISON OF HUMAN ALPHA1-PROTEINASE INHIBITOR FRACTION IV-1 WITH A1PI FROM FRACTION IV-1+4 FREE TO VIEW

Eva M. Muchitsch, DVM*; Susan M. Kubik, BSc; Wilfried Auer, DVM; Alfred Weber, PhD; Martin Wolfsegger, Mag; Peter L. Turecek, PhD; Jackie Kunzler, MSc, MBA; Jerome Gass, DVM; Hans P. Schwarz, MD
Author and Funding Information

Baxter BioScience, Vienna, Austria



Chest. 2006;130(4_MeetingAbstracts):183S. doi:10.1378/chest.130.4_MeetingAbstracts.183S-c
Text Size: A A A
Published online

Abstract

PURPOSE: Eight in vivo preclinical protocols were conducted to assess the profile of A1PI Fraction (Fr.) IV-1 paste in comparison to A1PI using Fr. IV-1+4 paste regarding biocomparability.

METHODS: The following biocomparability studies were conducted with A1PI Fr.IV-1 and Fr.IV-1+4: safety pharmacology in dogs (measurement of mean arterial and pulmonary artery pressure, cardiac output, stroke volume, total peripheral vascular resistance, heart rate, respiration rate, respiratory minute volume, ECG, platelet count and plasma fibrinogen concentration), bronchospastic activity in guinea pigs, hypotensive potential in spontaneously hypertensive rats (all determining anaphylactoid potential), pharmacokinetics (PK) in rats, acute and 30 day repeated dose toxicity including toxicokinetics in rats and a local tolerance study in rabbits. Negative reference items were administered using corresponding volumes.

RESULTS: Safety pharmacology testing in dogs, rats and guinea pigs showed neither anaphylactoid reactions nor development of disseminated intravascular coagulation after treatment with either A1PI Fr.IV-1, A1PI Fr.IV-1+4 or negative reference items. Positive reactions were induced in all animals by the subsequent injection of the immunoglobulin positive control, confirming the validity of the models. Pharmacokinetics: there were no significant differences in area under the curve and half life for test and reference items. Toxicology profile: there were no significant changes in any of the parameters evaluated. No antibody responses were detected. No substantial sex differences were observed in toxicokinetics during repetitive dose administration, steady state levels of A1PI were reached by day fifteen. Neither abnormalities in animal behavior nor alterations at the injection sites were observed in any group during local tolerance testing.

CONCLUSION: In all preclinical animal studies A1PI from Fr.IV-1 was bioequivalent to Fr.IV-1+4 regarding safety and PK.

CLINICAL IMPLICATIONS: Based on preclinical results, no differences regarding safety and efficacy can be expected in the clinical use of A1PI products from either Fr.IV-1 or Fr.IV-1+4 paste.

DISCLOSURE: Eva Muchitsch, Employee All authors are employees of Baxter BioScience.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543